Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Gilead Sciences  /  Forum Gilead geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Gilead Sciences OTC:GILD.Q, US3755581036

  • 67,750 15 apr 2024 22:00
  • 0,000 (0,00%) Dagrange 0,000 - 0,000
  • 27 Gem. (3M) 7,4M

Forum Gilead geopend

874 Posts
Pagina: «« 1 ... 13 14 15 16 17 ... 44 »» | Laatste | Omlaag ↓
  1. [verwijderd] 28 maart 2020 23:07
    quote:

    Kaspersky schreef op 28 maart 2020 23:04:

    [...]
    Technisch -> naar beneden maandag op $70,00 - $71,00.
    Dinsdag wordt mogelijk $74,00 weer getest.

    Gilead blijft bij mij long in de portefeuille staan.
    Dit verwacht ik ook. Ben benieuwd naar 3 April. Wat verwacht jij, zal de koers enorm omhoog gaan?
  2. [verwijderd] 28 maart 2020 23:15
    quote:

    Imjustabeginner schreef op 28 maart 2020 23:07:

    [...]

    Dit verwacht ik ook. Ben benieuwd naar 3 April. Wat verwacht jij, zal de koers enorm omhoog gaan?

    Technisch bepaald niet exact wat er gaat gebeuren; het lijkt erop dat we volgende week of de week daarop ook de $78,00 gaan testen. En dat zou best 3 april 2020 kunnen zijn: technisch is geen exacte voorspelling.

    Ik voorzie bijvoorbeeld een explosieve stijging maar wel binnen een periode van 2 jaar (vrij ruim). De 78,00 dollar lijkt binnenkort weer in beeld te komen.

    De algoritmen kunnen de koers nog 2 jaar zijwaarts laten gaan (als je dividend meerekent is het nog steeds een stijging); om daarna als iedereen eruit is geschud met grotere percentages te gaan stijgen.
  3. Ralph01A 28 maart 2020 23:48
    Gilead CEO: We're on track to have initial data in the coming weeks

    Mar. 28, 2020 6:19 PM ET|About: Gilead Sciences, Inc. (GILD)|By: SA Eli Hoffmann, SA News Editor
    In an open letter, Gilead (NASDAQ:GILD) CEO Daniel O'Day says he expects to have initial data about the potential of remdesivir to combat coronavirus "in the coming weeks."

    "When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19," he writes.

    "Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need.

    "In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This 'compassionate use' program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients.

    "With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time. While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people."

    Als gilead slechte resultaten terug zou hebben gekregen op de meer dan 1000 patienten aan wie al remdesivir al is verstrekt zouden ze dit persbericht waarschijnlijk niet zo proactief naar buiten hebben gebracht.
  5. forum rang 5 Endless 29 maart 2020 00:05
    Steking alpha
    Gilead CEO: We're on track to have initial data in the coming weeks

    Mar. 28, 2020 6:19 PM ET|About: Gilead Sciences, Inc. (GILD)|By: SA Eli Hoffmann, SA News Editor
    In an open letter, Gilead (NASDAQ:GILD) CEO Daniel O'Day says he expects to have initial data about the potential of remdesivir to combat coronavirus "in the coming weeks."

    "When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19," he writes.

    "Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need.

    "In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This 'compassionate use' program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients.

    "With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time. While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people."

    Last week, Gilead dropped its orphan drug designation for remdesivir, a status granted by the FDA that would have extended monopoly rights for the drug if it came on the market.
  6. [verwijderd] 29 maart 2020 00:13
    Er zijn meerdere biotech die mogelijk een medicijn hebben voor Covid 19. Het zou leuk zijn als Gilead het heeft en de productie flink kan opschalen, maar persoonlijk zou ik het niet erg vinden als andere biotechbedrijven deze prijs binnenslepen.
    Gilead heeft ook goede diversificatie; een medicijn voor Covid 19 zou bij succes wel de oorzaak kunnen zijn voor de explosieve stijgingen.

    Tussen nu en 2022 verwacht ik explosieve stijgingen -> opvallend zijn de extra bewegingen van de afgelopen tijd. Mogelijk om wat aandelen los te krijgen.
  8. Ralph01A 29 maart 2020 11:32
    amp.usatoday.com/amp/2934583001?__twi...

    To expedite access, the company announced Saturday it had begun transitioning to a system using an "expanded access" program. This allows hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at a time.

    We are doing this before knowing whether the drug is safe and effective to treat COVID-19 because of the urgency of the situation,” a company spokeswoman said via email.
  10. forum rang 5 Endless 30 maart 2020 16:14
    Gilead nearing finish line on Forty Seven buy

    Mar. 30, 2020 8:40 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (NASDAQ:GILD) announces the expiration of the HSR waiting period regarding its previously announced acquisition of Forty Seven (NASDAQ:FTSV) for ~$4.9B. The transaction should close in early April.

    GILD is up 3% premarket on the advancement of remdesivir for the treatment of COVID-19.
  11. forum rang 4 Bakkiekoffie 30 maart 2020 16:17
    quote:

    Bakkiekoffie schreef op 30 maart 2020 16:13:

    Voor de derde keer in korte tijd zit GLD met koers rond $79/80,-
    In de boekjes vroeger grote kans op doorbraak.
    Pat op zich ook wel bij het nieuws wat er speelt, maar dat acht ik bij de tweede bounce ook al. Wat verwachten jullie?

    Sorry, ik zag verkeerde koers. (Teveel positief zonlicht). We zitten in de € 76,-
    Dus vraag is nog niet opportuun
  13. forum rang 5 Endless 31 maart 2020 21:49
    Good Reason To Be Hopeful For Gilead's Remdesivir

    Mar. 31, 2020 2:33 PM ET|12 comments | About: Gilead Sciences, Inc. (GILD)
    Richelle Cutler-Strom
    Richelle Cutler-Strom
    Long/short equity, Growth, growth at reasonable price, short-term horizon

    (221 followers)
    Summary
    Gilead is testing efficacy of remdesivir against the novel coronavirus (COVID-19) in multiple international trials.

    Remdesivir prevented severe lung damage from MERS coronovirus infection in a mouse and monkey model.

    Preclinical data and an explanation for the Ebola trial failure indicate that remdesivir will be a successful treatment for COVID-19.

    Inevitable remdesivir licensing deals, with exclusivity until 2034, and its forthcoming marketing of a blockbuster arthritis drug, filgotinib, will increase Gilead's revenue significantly.

    Gilead Sciences Inc. (NASDAQ:GILD) is currently testing remdesivir in multiple human trials for efficacy against the novel coronavirus (COVID-19). Remdesivir is an adenosine nucleotide prodrug that inhibits replication in a broad range of viruses (Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxovirida) in vitro. Remdesivir reduced lung damage inflicted from the MERS coronavirus in mice and monkeys. The animal studies showed that optimal therapeutic efficacy requires early dosing. However, MERS patients were found to have prolonged viral replication, so remdesivir may still benefit the most severe coronavirus cases.

    Remdesivir failed in Ebola virus trials even though remdesivir inhibited Ebola virus replication in vitro and in a monkey study. These preclinical studies indicated that remdesivir would be effective against the Ebola virus in humans. So, what went wrong? Could disappointment be around the corner for remdesivir in the COVID-19 trials?

    The Ebola monkey study showed that a high remdesivir concentration (10 mg/kg) was critical for maximum suppression. The trial also indicated that too high a concentration, over consecutive days, could cause liver injury. Gilead played it safe by using a low dosage in the Ebola trial (~3 mg/kg loading dose, 1.5 mg/kg maintenance dose, assuming a 66 kg patient). Thus, the dosage may not have reached an effective concentration in all cell types. Furthermore, Ebola causes systemic intravascular coagulation, which could have restricted remdesivir circulation through organs. The stronger efficacy of the Ebola targeting antibodies could be attributed to their ability to enter the lymphatic system, circumventing the coagulated capillaries - the antibodies could reach infected cells, whereas remdesivir could not.

    Gilead is using the same remdesivir dosage in the COVID-19 trials as used in the Ebola trial. Fortunately, COVID-19 infected patients do not have circulatory problems. Also, COVID-19 targets the lungs, and remdesivir robustly inhibits COVID-19 replication in human airway epithelial cells in vitro. The selected trial dosage is based on the effective in vitro inhibitory concentration along with in vivo pharmacokinetics and toxicity data. Accordingly, lung epithelial cells of COVID-19 infected patients receive an effective concentration of remdesivir. Remdesivir may also be more readily incorporated into coronavirus RNA than Ebola RNA since remdesivir appears to have a higher affinity for the coronavirus polymerase than the Ebola polymerase.

    A blogger recently opined remdesivir's unpredictable success based on the poor performance of a similar type of drug, favipiravir. However, favipiravir has never been reported to inhibit coronavirus replication (figure 2). Moreover, many nucleoside analogues fail to inhibit virus replication because the virus’s proofreading nuclease detects and removes them. Remdesivir mostly evades proofreading by the coronavirus exoribonuclease, thus allowing incorporation and viral inhibition.

    Nucleoside and nucleotide analogues are tried and true antiviral drugs, making up almost half of all antivirals. Chloroquine is another antiviral that has shown promise in treating COVID-19. Unfortunately, chloroquine can have serious side effects such as vomiting, diarrhea, nausea, and headache. These side effects may be particularly hazardous in ill COVID-19 patients and is out of the question for intubated patients.

    RNA viruses have high mutation rates and mutations in COVID-19 surface glycoproteins could eventually make the current vaccines under development less effective. An annual vaccine version, like the flu vaccine, may be necessary. Moreover, vaccines produce less protection in the elderly. Thus, a vaccine will not make remdesivir obsolete. Remdesivir's efficacy relies on polymerase nucleotides conserved across diverse coronavirus strains. This indicates that remdesivir will be front-line therapy for today's COVID-19 and tomorrow's new coronavirus strain. Gilead's first remdesivir patent filing was in 2014, which gives Gilead exclusivity rights until 2034.

    The first remdesivir trial result from China has an estimated primary completion date of April 3rd. With a life-saving treatment in high demand, the analysis could be expedited. Good news could be just around the corner.

    Financials

    Gilead's revenue growth has been low, with the 12 months trailing growth at a paltry 1.2%. However, Gilead still has a reasonable P/E of 17.3 and earnings will grow markedly if Gilead receives licensing revenue from remdesivir. In addition, Gilead and Galapagos (NASDAQ:GLPG) will soon bring Filgotinib to market for treating rheumatoid arthritis. Filgotinib will compete with AbbVie's (NYSE:ABBV) Rinvoq, but Gilead is hoping its strong safety record prevents a black box warning, making filgotinib the preferred treatment. Filgotinib's approval for treating other inflammatory diseases, such as Ulcerative colitis, Crohn's disease, Psoriatic arthritis, and Ankylosing spondylitis, will soon follow. The potential worldwide sales of these indications are in the billions.
  14. Ralph01A 31 maart 2020 23:46
    www.timesofisrael.com/israeli-doctor-...

    In Padua, the autoimmune medicine Tocilizumab has proven effective, but can only be used once it is established that no other viruses or bacteria are present in the patients’ bodies, he said. The hospital where he works has also seen positive results from the antiviral drug Remdesivir, he added.

    Een ervaring van een arts in italie.
  15. forum rang 5 Endless 1 april 2020 14:20
    Gilead Sciences launches two remdesivir studies in UK

    Apr. 1, 2020 7:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (NASDAQ:GILD) has initiated two Phase 3 clinical trials in the UK evaluating remdesivir in moderately-to-severely ill COVID-19 patients. 15 sites will be initially involved.
  16. forum rang 10 DeZwarteRidder 1 april 2020 14:32
    quote:

    Endless schreef op 1 april 2020 14:20:

    Gilead Sciences launches two remdesivir studies in UK

    Apr. 1, 2020 7:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (NASDAQ:GILD) has initiated two Phase 3 clinical trials in the UK evaluating remdesivir in moderately-to-severely ill COVID-19 patients. 15 sites will be initially involved.
    Gelukkig zijn er genoeg proefpersonen........
874 Posts
Pagina: «« 1 ... 13 14 15 16 17 ... 44 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Aantrekkelijk gewaardeerd Gilead is niet issue-vrij

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Gilead Sciences Nieuws

  1. 03 aug Gilead verlaagt outlook
  2. apr '23 Gilead schiet tekort
  3. feb '23 Hogere resultaten Gilead
  4. aug '22 Hogere omzet Gilead
  5. apr '22 Gilead verlaagt outlook
  6. feb '22 Schikking drukt winst Gilead
  7. okt '21 Gilead verhoogt outlook
  8. apr '21 Gilead profiteert minder van remdesivir
  9. apr '21 Biden wil medicijnkosten flink verlagen - media 14
  10. apr '21 Goedkeuringsaanvraag voor filgotinib ingediend in Japan voor behandeling darmziekte

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!